Jun Peng

6.6k total citations
158 papers, 4.5k citations indexed

About

Jun Peng is a scholar working on Hematology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Jun Peng has authored 158 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Hematology, 52 papers in Immunology and 30 papers in Pathology and Forensic Medicine. Recurrent topics in Jun Peng's work include Platelet Disorders and Treatments (110 papers), Blood groups and transfusion (42 papers) and Autoimmune Bullous Skin Diseases (27 papers). Jun Peng is often cited by papers focused on Platelet Disorders and Treatments (110 papers), Blood groups and transfusion (42 papers) and Autoimmune Bullous Skin Diseases (27 papers). Jun Peng collaborates with scholars based in China, Canada and United States. Jun Peng's co-authors include Ming Hou, Yu Hou, Ping Qin, Li-Zhen Li, Xinguang Liu, Lin Wang, Xuebin Ji, Linlin Shao, Chengshan Guo and Chengjiang Gao and has published in prestigious journals such as Nature Communications, Blood and The Journal of Immunology.

In The Last Decade

Jun Peng

152 papers receiving 4.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jun Peng China 38 2.7k 1.1k 962 959 683 158 4.5k
Ming Hou China 39 3.8k 1.4× 1.1k 1.0× 622 0.6× 1.2k 1.2× 914 1.3× 249 5.3k
Thomas Luther Germany 39 2.3k 0.8× 649 0.6× 1.7k 1.7× 122 0.1× 704 1.0× 84 5.5k
Virgilio Evangelista Italy 34 1.3k 0.5× 927 0.9× 883 0.9× 170 0.2× 429 0.6× 75 3.9k
Daniel T. Eitzman United States 38 1.1k 0.4× 1.3k 1.2× 1.0k 1.0× 141 0.1× 335 0.5× 100 5.2k
Sara Teresinha Olalla Saad Brazil 34 1.6k 0.6× 572 0.5× 1.7k 1.8× 261 0.3× 1.4k 2.0× 298 4.5k
Nicole C. Kaneider Austria 36 905 0.3× 730 0.7× 1.1k 1.1× 163 0.2× 256 0.4× 62 3.2k
François Lanza France 51 3.9k 1.4× 873 0.8× 1.5k 1.6× 128 0.1× 572 0.8× 195 7.1k
Roberta Donadelli Italy 30 811 0.3× 2.0k 1.8× 701 0.7× 176 0.2× 370 0.5× 53 4.2k
Hartmut Weiler United States 35 2.2k 0.8× 691 0.6× 1.2k 1.2× 66 0.1× 536 0.8× 121 4.5k
Yukitaka Ueki Japan 33 535 0.2× 990 0.9× 640 0.7× 216 0.2× 257 0.4× 160 3.5k

Countries citing papers authored by Jun Peng

Since Specialization
Citations

This map shows the geographic impact of Jun Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun Peng more than expected).

Fields of papers citing papers by Jun Peng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jun Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun Peng. The network helps show where Jun Peng may publish in the future.

Co-authorship network of co-authors of Jun Peng

This figure shows the co-authorship network connecting the top 25 collaborators of Jun Peng. A scholar is included among the top collaborators of Jun Peng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jun Peng. Jun Peng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Han, Fengjiao, Qiuyu Guo, Lin Han, et al.. (2025). CD19 chimeric antigen receptor‐T cell therapy in murine immune thrombocytopenia. British Journal of Haematology. 206(5). 1430–1442. 1 indexed citations
2.
Sun, Lu, Juan Wang, Chenglu Yuan, et al.. (2024). Eltrombopag plus diacerein vs eltrombopag in patients with ITP: a multicenter, randomized, open-label phase 2 trial. Blood. 144(17). 1791–1799. 2 indexed citations
3.
4.
Liu, Qiang, Qi Feng, Xiaorong Yang, et al.. (2023). Obesity is associated with poor outcomes of corticosteroid treatment in patients with primary immune thrombocytopenia. British Journal of Haematology. 203(2). 295–303. 2 indexed citations
5.
Wang, Yin, Qi Feng, Shuwen Wang, et al.. (2023). Plasma long noncoding RNAs lncDC and THRIL as potential diagnostic markers of adult primary immune thrombocytopenia. International Journal of Laboratory Hematology. 45(4). 481–488. 1 indexed citations
6.
Qin, Jing, Qiang Liu, Anli Liu, et al.. (2022). Empagliflozin modulates CD4+ T‐cell differentiation via metabolic reprogramming in immune thrombocytopenia. British Journal of Haematology. 198(4). 765–775. 18 indexed citations
7.
Liu, Yan, Yin Wang, Cheng Zhang, et al.. (2022). HDAC3 single‐nucleotide polymorphism rs2530223 is associated with increased susceptibility and severity of primary immune thrombocytopenia. International Journal of Laboratory Hematology. 44(5). 875–882. 2 indexed citations
8.
Li, Ranran, Shuwen Wang, Linlin Shao, et al.. (2022). Association of metformin treatment and outcome in adult patients with ITP and pre‐existing T2DM. British Journal of Haematology. 197(3). 367–372. 2 indexed citations
9.
Ni, Xiaofei, Lingjun Wang, Haoyi Wang, et al.. (2022). Low-dose decitabine modulates myeloid-derived suppressor cell fitness via LKB1 in immune thrombocytopenia. Blood. 140(26). 2818–2834. 12 indexed citations
10.
Han, Panpan, Yu Hou, Yajing Zhao, et al.. (2021). Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia. Blood. 138(8). 674–688. 47 indexed citations
11.
Yu, Yafei, Yu Hou, Yajing Zhao, et al.. (2021). Platelet autoantibody specificity and response to rhTPO treatment in patients with primary immune thrombocytopenia. British Journal of Haematology. 194(1). 191–194. 10 indexed citations
12.
Hou, Yu, Panpan Han, Yajing Zhao, et al.. (2021). Proteomic analysis and microRNA expression profiling of plasma‐derived exosomes in primary immune thrombocytopenia. British Journal of Haematology. 194(6). 1045–1052. 14 indexed citations
13.
Hua, Mingqiang, Ju Li, Chunyan Wang, et al.. (2019). Aberrant expression of microRNA in CD4+ cells contributes to Th17/Treg imbalance in primary immune thrombocytopenia. Thrombosis Research. 177. 70–78. 31 indexed citations
14.
Peng, Jun, et al.. (2019). Amino sugar metabolism pathway involved in chlamydospore formation of Fusarium oxysporum f. sp. cubense.. Mycosystema. 38(4). 485–493. 3 indexed citations
15.
Xu, Miao, June Li, Miguel A. D. Neves, et al.. (2018). GPIbα is required for platelet-mediated hepatic thrombopoietin generation. Blood. 132(6). 622–634. 50 indexed citations
16.
Qin, Ping, Shan Xiao, Hai Zhou, et al.. (2017). A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood. 130(9). 1097–1103. 75 indexed citations
17.
Han, Panpan, Yajing Zhao, Hai Zhou, et al.. (2017). Low-Dose Decitabine Restores Immune Tolerance in ITP By Modulating Regulatory T Cells. Blood. 130. 229–229. 3 indexed citations
18.
Amash, Alaa, Lin Wang, Yawen Wang, et al.. (2016). CD44 Antibody Inhibition of Macrophage Phagocytosis Targets Fcγ Receptor– and Complement Receptor 3–Dependent Mechanisms. The Journal of Immunology. 196(8). 3331–3340. 22 indexed citations
19.
Wei, Yu, Xuebin Ji, Yawen Wang, et al.. (2015). High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 127(3). 296–302. 145 indexed citations
20.
Ma, Daoxin, Jianjian Dai, Xiaojuan Zhu, et al.. (2009). Aberrant expression of Notch signaling molecules in patients with immune thrombocytopenic purpura. Annals of Hematology. 89(2). 155–161. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ming Hou Breakdown of academic impact, for papers by Thomas Luther Breakdown of academic impact, for papers by Virgilio Evangelista Breakdown of academic impact, for papers by Daniel T. Eitzman Breakdown of academic impact, for papers by Sara Teresinha Olalla Saad Breakdown of academic impact, for papers by Nicole C. Kaneider Breakdown of academic impact, for papers by François Lanza Breakdown of academic impact, for papers by Roberta Donadelli Breakdown of academic impact, for papers by Hartmut Weiler Breakdown of academic impact, for papers by Yukitaka Ueki
Rankless by CCL
2026